What the Zolgensma tumour reports mean for Novartis and AAV gene therapy safety
FDA is investigating Zolgensma malignancy risk after vector DNA integration was found in two tumours. Novartis has received nine reports.
Pharma & Biotech
Pharma & Biotech
How Rhapsido’s symptomatic dermographism approval expands Novartis immunology strategy
Novartis’ Rhapsido won the first FDA label for symptomatic dermographism after a 29.3% complete response in Phase 3 RemIND.
Features & Analysis
Novartis paid $12bn for Avidity Biosciences. What does del-desiran’s Phase 3 failure do to the deal thesis?
Novartis’ acquisition of Avidity Biosciences brought three late-stage antibody oligonucleotide conjugate programmes into its neuromuscular pipeline. The failure of del-desiran’s Phase 3 HARBOR study now forces investors to separate a damaging lead-asset setback from the value that may remain elsewhere in the platform.
Medical Devices & Diagnostics
Novartis bets on Texas as radioligand therapy moves closer to mainstream oncology
RLT demand is rising faster than supply chains can stretch. Novartis’ Texas buildout tests whether precision oncology can scale.
Pharma & Biotech
Why Avidity is spinning off Atrium Therapeutics before the Novartis acquisition closes
Avidity Biosciences sets spin-off record date for Atrium ahead of Novartis deal. Find out what this carve-out reveals about RNA platform risk and M&A strategy.
Pharma & Biotech
Allergy relief shake-up: Dr. Reddy’s launches generic Pataday 0.7% eye drops
Dr. Reddy’s launches first U.S. generic of Pataday 0.7% eye drops. Find out what this means for the OTC allergy market and Novartis’s branded edge.
Pharma & Biotech
Can a global trials map help fix spondyloarthritis’s fragmented development landscape?
Explore what global spondyloarthritis trial trends in 2025 reveal about innovation gaps, sponsor risk, and regulatory hurdles. Read the full industry analysis.
Pharma & Biotech
Oral complement therapy for myasthenia gravis? Novartis’ iptacopan enters the neurology arena
Novartis gains FDA orphan status for iptacopan in myasthenia gravis. Explore how this oral complement inhibitor could challenge biologics in neurology.